| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
MSC2360844 manufacturers
- MSC2360844
-
- $48.00
-
2026-07-27
- CAS:1305267-37-1
- Purity: 99.54%
- Supply Ability: 10g
- MSC2360844
-
- $48.00
-
2026-07-27
- CAS:1305267-37-1
- Purity: 99.54%
- Supply Ability: 10g
|
| | MSC2360844 Basic information |
| Product Name: | MSC2360844 | | Synonyms: | MSC2360844;Phosphoinositide 3-kinase,MSC 2360844,MSC2360844,cells,SLE-prone,primary,Inhibitor,functions,inhibit,PI3K,proliferation,MSC-2360844;Methanone, [6-fluoro-1,4-dihydro-1-[4-(4-morpholinylmethyl)phenyl]-5,5-dioxido[1]benzothiopyrano[4,3-c]pyrazol-3-yl]-4-morpholinyl-;(6-fluoro-1-(4-(morpholinomethyl)phenyl)-5,5-dioxido-1,4-dihydrothiochromeno[4,3-c]pyrazol-3-yl)(morpholino)methanone;MSC2360844(IOA-244 /roginolisib);MSC2360844, 10 mM in DMSO;IOA 244;IOA244 | | CAS: | 1305267-37-1 | | MF: | C26H27FN4O5S | | MW: | 526.58 | | EINECS: | | | Product Categories: | | | Mol File: | 1305267-37-1.mol |  |
| | MSC2360844 Chemical Properties |
| Boiling point | 779.8±60.0 °C(Predicted) | | density | 1.50±0.1 g/cm3(Predicted) | | pka | 6.05±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | MSC2360844 Usage And Synthesis |
| Uses | Roginolisib (MSC2360844; IOA-244) is a potent, orally active and selective PI3Kδ inhibitor, with an IC50 of 145 nM. Roginolisib shows highly selective against a panel of 278 additional kinases[1]. | | in vivo | Roginolisib (6.6-66 mg/kg; daily from week 2 to 10) ameliorates disease manifestations in a murine SLE model[1]. | Animal Model: | NZB/W F1 female mice[1] | | Dosage: | 6.6, 22, or 66mg/kg | | Administration: | Oral; starting at week 2 post ADV-IFNα delivery, once daily at 10weeks | | Result: | Significantly reduced proteinuria incidence and severity in a dose-dependent manner.
|
| | IC 50 | PI3Kδ: 145 nM (IC50); PI3Kα: 18500 nM (IC50); PI3Kβ: 2850 nM (IC50) | | References | [1] Haselmayer P, et al. Characterization of Novel PI3Kδ Inhibitors as Potential Therapeutics for SLE and Lupus Nephritis in Pre-Clinical Studies. Front Immunol. 2014 May 22;5:233. DOI:10.3389/fimmu.2014.00233 |
| | MSC2360844 Preparation Products And Raw materials |
|